{"name":"Jonsson Comprehensive Cancer Center","slug":"jonsson-comprehensive-cancer-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Zipalertinib","genericName":"Zipalertinib","slug":"zipalertinib","indication":"Other","status":"phase_2"},{"name":"androgen deprivation therapy","genericName":"androgen deprivation therapy","slug":"androgen-deprivation-therapy","indication":"Other","status":"phase_3"},{"name":"trastuxumab","genericName":"trastuxumab","slug":"trastuxumab","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"bortezomib + rituximab","genericName":"bortezomib + rituximab","slug":"bortezomib-rituximab","indication":"B-cell non-Hodgkin lymphoma","status":"phase_3"}]}],"pipeline":[{"name":"Zipalertinib","genericName":"Zipalertinib","slug":"zipalertinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"androgen deprivation therapy","genericName":"androgen deprivation therapy","slug":"androgen-deprivation-therapy","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bortezomib + rituximab","genericName":"bortezomib + rituximab","slug":"bortezomib-rituximab","phase":"phase_3","mechanism":"Bortezomib inhibits the proteasome to trigger cancer cell death, while rituximab targets CD20 on B cells to enhance immune-mediated tumor destruction.","indications":["B-cell non-Hodgkin lymphoma","Mantle cell lymphoma"],"catalyst":""},{"name":"trastuxumab","genericName":"trastuxumab","slug":"trastuxumab","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQUTdUQXlmdzZLQmdhT2JDVEloUEdOZDA4SGVEMHhHTFB2VlBtWkJjX0J4ZndQalhmaDNoVTBycm0tRGV0S215UXllcE9aaWM2U0N1QTlCMXlqWGJPM25iZkY1MkJlNzRNS195cDZ3WUxDY3ZnWTZRMTFTaE1DelJjaTBOTnNneWptQW9BMTZFdXFzRzZiakF2ZXZHSWdndw?oc=5","date":"2026-03-03","type":"pipeline","source":"UCLA Health","summary":"New therapy combines imaging and targeted radiation to treat aggressive bone cancer - UCLA Health","headline":"New therapy combines imaging and targeted radiation to treat aggressive bone cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA4WEpKUkZxVHJwUGZlU0xDX2VxZ2laRlg4cWdTSnlJYVI3eU00M0JzMHhEUjgtT2NkeEIxcmFkN1liaFkxZFF4dWZXQ21tNHRpWjBsYy0tU2pURTNxNU1IYTh1QU1uYm9j?oc=5","date":"2026-02-27","type":"trial","source":"MedPage Today","summary":"Study Questions Use of Prostate Cancer Hormone Therapy in Certain Cases - MedPage Today","headline":"Study Questions Use of Prostate Cancer Hormone Therapy in Certain Cases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPQzdhcUMyX3k2ZDJLUFZEZTAyVHk2MkRyZk84T3NEOFdUTXdaUy05eWgwYXMyX3g0eWpvSndPYXVQcFdTakM5MEJ1T21Qa0dSbWdWb28yc1NtbTdNeXFMMnR3YjJ3ODF4QVI0dDJGUmN3U0Y2dkV5Z2hTQnl2MFdKcUIybUJuRkVNeHFDV3ZXUHlnbExfTndUU0NNcVE4YWNtYkdNa2o4TWNoTEljNUZwU25tdnE1NXM?oc=5","date":"2025-12-17","type":"pipeline","source":"Oncology News Central","summary":"Oncologists and Cancer Care May Suffer Under New Medicare Drug Pay Cuts - Oncology News Central","headline":"Oncologists and Cancer Care May Suffer Under New Medicare Drug Pay Cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPQWVnUXlCdk9kYTFYeUozdFotYVR3WkpzQ19HdEQ2VXpZUE80RVNTVW9xM204NEthU21OM1ZhNjM1bVFXbFF4aXB6VUxfdHJwN1RnZWdCQWVIbWd6M2NnV3kwUElYeEVSMjlGQXg3cnU5cFB0b1hpaE1SbDNncDZybjUxTWtuWURSTkhtUl93ejFPNDdnSUFTb0lnWnN4aVFYRm5rN1R5S19fendsS2lkc2NBODdWOGc?oc=5","date":"2025-12-11","type":"pipeline","source":"The Pharma Letter","summary":"Roche hails giredestrant effect in ER-positive early-stage breast cancer - The Pharma Letter","headline":"Roche hails giredestrant effect in ER-positive early-stage breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQRUpjbDBqaEJBR3dGOEFOR0R6LS0xTks5V1QwN1BLbHNaRFdlOXliTWlkMlN5TXQ1ZEw4WkxIUTlyeUZDbFduVVlfbXRKelVydkZKbkpUY1ZhNzJac3dsQU9hQW96cW1tbzBQWjREeHJLcE5IbnI5dG03cHRpTXdtd3lmdmNNYW5LV01IbF9PcWJnZmhkYXoyOUxjcnpGMVF6RVVsTjItX2g1R19jOVBmX1hQRS1nX053WGdFT3lUOFFXQQ?oc=5","date":"2025-10-16","type":"trial","source":"Fierce Pharma","summary":"J&J heads to regulators with Tecvayli-Darzalex combo's phase 3 win as earlier myeloma treatment - Fierce Pharma","headline":"J&J heads to regulators with Tecvayli-Darzalex combo's phase 3 win as earlier myeloma treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1LbW9fNldiZmY2RURHS2I2aGUzTWZrVnpHaWJzZ203QlpzbUl4VS0zekczYTNYWGw5UXFoWF9odF9XaG0wQXNLZUVFT2F2dGFSOGlDRVU0OU83Wl94NzRub3ZidEdiTVpESEEtV1RGdVg?oc=5","date":"2025-10-06","type":"pipeline","source":"labusinessjournal.com","summary":"49. Arie Belldegrun - labusinessjournal.com","headline":"49. Arie Belldegrun","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNeVlhMWFfeFdjY2RBXzNTTXR0cllLemhRRFpfTVBuMXdIdURPY0IwTXBmYzRLRnNkbHI2VEhhWVprb2JVWjQ4QVQtRmhLSEx0S0JSZ2hnbTdoMENodUlsTHdnazBmYVF2WU5IbVBTNVF2UGc4aUREdDBaYk8yeU5rR21BNlhibXVFXzNsOVVaNmQxM0NqRDZfX1BIVThwM3IzRGhMRHRTdHFDdDRhT0NRN0xTRTVURlRybkc1SEVBcmNBek5nd1doR2ZVWjZnQUZOanliS1FyTmhHNE16YTVFUHI0NEVUdUxGZURvNks5dDh6c3lCYmJ3?oc=5","date":"2025-09-09","type":"regulatory","source":"Johnson & Johnson","summary":"U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated - Johnson & Johnson","headline":"U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQMUp4OGhLc2E3M2pFZE56Q2lDeXl5V1VVbGF2b0gzdTBZX1VuaUxTd2FyNkNram9sOVl1MXR6ZU1EWWRCUDUwNnloLXZsUlI3RDVVMzltMHNtanJ4cm9KNWZnRzdTcGNxVUtQaUJNMGVEdVN1aTRNMGdBdDRZYk5lTm03b25FbnNVdUUzbUtja2VPeEt6NlBuXw?oc=5","date":"2025-06-30","type":"pipeline","source":"Pharmaceutical Executive","summary":"Oncology Care Index Spurs J&J to Address Fragmentation in Cancer Treatment - Pharmaceutical Executive","headline":"Oncology Care Index Spurs J&J to Address Fragmentation in Cancer Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQNkNOTC1pQ2VFYlp3RVJ3VXJZQndRODgzcjZFOTkwS3pwVWlmbWtqNVBJd3ZQbmEtc3ZNc19MdXpOekxySnRNVy0xRkpIN2dkRm5hS0lFYW5leUVKdTVOM1Vwb1l6WTdqUEd2QVZ3R1NaMjJjS1NQcWVxdi1ueFRvWmRSeW5jU1ZMdjFhbVd2S0dCbVZRaHc2Z3NNVE1iVlpQSkM0UUVwb0lHMjhIeGh2c2hsUk9nZE1wRVgxVXhZR3YwaENsbVE?oc=5","date":"2025-01-30","type":"pipeline","source":"U.S. News & World Report","summary":"How UCLA Health’s Legacy of Theranostics Innovation Transforms Cancer Care - U.S. News & World Report","headline":"How UCLA Health’s Legacy of Theranostics Innovation Transforms Cancer Care - U.S. News & World Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNMDVPNUFLaUN2dm1FWWlQMmlQYkZRTDNwdDVIT3BmLW1LekRhSHc3TmFpU1JKSzU5V2dJZXBzLVRiakdYZ25WcGVsUmRFb1V0STZWMUJib0hnSndnSzFVdGh4azZQcnAzUVpHSl93ZTBHblBrSlI3REUtdC1hcXQzNEpDWkZoZ0ZNOTc5WFU2anB6dGZKbGtNaVZB?oc=5","date":"2024-05-01","type":"deal","source":"UCLA Health","summary":"Biotech Firm Launched by Jonsson Cancer Center Scientists Acquired by Pharmaceutical Company - UCLA Health","headline":"Biotech Firm Launched by Jonsson Cancer Center Scientists Acquired by Pharmaceutical Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1jS1Z3dkpWazZWc0N6Mk5KOTlfaUNQYzBfMEZYTi04Yko1T0ZOZldWU1FBS0hnMjlQWEhuVXBFUTFoNVpOaDRoYXdJZmFUNEdyZ2Z3emQ1NXZjOHR0eUJGcFRB?oc=5","date":"2021-04-09","type":"pipeline","source":"The Cancer Letter","summary":"Founders: Roswell Park’s Dr. Roswell Park and UCLA’s Kenneth Jonsson - The Cancer Letter","headline":"Founders: Roswell Park’s Dr. Roswell Park and UCLA’s Kenneth Jonsson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOUDZSelF6SVYwcGJySGtoNGRDUVVMd3N2UlJGWE9vbTFjQ2JBS0NXaFdDeTlkTkJUVURFSUVpQ0F5djNkVENWbzh6YlNSdEE3akZ6SUtyQ2RqWkVTSTZXV0RfVFJETC10enRZMWpVRWdHcFhNcnU5c1lDXzZ4bGJIMFc1bTZtT01GbXV2UWVFbUpwdVRwTkgydFNIQWJwc0hZTGQtenJTN3RFbDhLWnBoSGNn?oc=5","date":"2017-08-10","type":"pipeline","source":"Newsroom | UCLA","summary":"Michael Teitell named director of the UCLA Jonsson Comprehensive Cancer Center - Newsroom | UCLA","headline":"Michael Teitell named director of the UCLA Jonsson Comprehensive Cancer Center - Newsroom | UCLA","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"phase_3":3},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}